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PENGHASILAN BIOAKTIF DERMIS DARI LACTOBACILUS DAN 
BIFIDOBAKTERIUM TERPILIH, DENGAN TUMPUAN KHAS KE ATAS 
PENGOPTIMUMAN SPHINGOMYELINASE AKTIVITI  LACTOBACILLUS 
RHAMNOSUS FTDC 8313 DENGAN KEHADIRAN MN2+ AND MG2+ 
 
ABSTRAK 
Laktobasilus dan bifidobakterium adalah antara genus probiotik yang paling 
lazim memiliki potensi yang terdokumentasi keatas kesihatan usus. Kajian terbaru 
mencadangkan bahawa potensi tersebut boleh menjangkaui kesejahteraan usus, 
contohnya untuk kesihatan kulit. Penyelidikan ini bertujuan untuk menilai 
penghasilan bahan bioaktif yang penting untuk kesihatan kulit dari laktobasilus dan 
bifidobakterium yang ditumbuhkan dalam susu. Kandungan asid lipoteikoik di dalam 
pecahan dinding sel adalah lebih tinggi (P < 0.05) dalam Lactobacillus rhamnosus 
FTDC 8313 dan Bifidobacterium longum BL 8643 dibandingkan dengan strain lain 
yang dikaji. Sementara itu, semua strain yang dikaji menunjukkan kepekatan 
peptidoglikan dinding sel yang sama. Keputusan kami menunjukkan bahawa 
laktobasilus mampu menghasilkan kepekatan asid hyaluronik dan diasetil yang lebih 
tinggi daripada bifidobakterium. Laktobasilus dan bifidobakterium yang dikaji juga 
menghasilkan sphingomyelinase (SMase) asid dan neutral, suatu enzim yang 
menjana seramida dan seterusnya mamainkan peranan penting dalam pembangunan 
sekatan fizikal pada stratum korneum (SC). 
Aktiviti SMase yang dihasilkan oleh L. rhamnosus FTDC 8313 juga telah 
dioptimumkan dengan menggunakan ion logam dwivalen melalui metodologi gerak 
balas permukaan. Dengan menggunakan reka bentuk faktorial penuh untuk 
penyaringan faktor, hanya magnesium sulfat (MgSO4) dan mangan sulfat (MnSO4) 
xv 
 
mempengaruhi aktiviti SMase secara signifikan (P < 0.001), manakala kesan kalsium 
sulfat (CaSO4) adalah tidak ketara (P > 0.05). Satu matriks reka bentuk komposit 
pusat (nilai alfa ± 1.414) telah dijana dengan dua faktor bebas iaitu, MnSO4 dan 
MgSO4. Gerak balas permukaan tiga dimensi meramalkan aktiviti SMase mencapai 
nilai optimum 6.52 mU ml-1, melalui kombinasi 3.85 mmol L-1  MnSO4 3.33 mmol 
L-1 MgSO4. Data yang diperolehi daripada eksperimen pengesahan menunjukkan 
sisihan 1.07% daripada nilai yang diramalkan, mengesahkan ramalan dan 
mempamirkan kebolehpercayaan model regresi yang digunakan. Kesan ion logam 
dwivalen keatas ciri-ciri pertumbuhan dan penghasilan bahan bioaktif lain, iaitu asid 
hyaluronik, diasetil, peptidoglikan, asid lipoteikoik, asid laktik, dan asid asetik dalam 
rantau aktiviti SMase dioptimumkan juga dinilai menggunakan gerak balas 
permukaan tiga dimensi.  
Kesan ion logam dwivalen keatas aktiviti Smase juga dikaji selanjutnya 
dengan menggunakan simulasi molekular. Pengedokan molekul menunjukkan 
bahawa penambahan Mn2+ dan Mg2+ ke tapak aktif SMase meningkatkan afiniti 
penambatan antara SMase dan sphingomyelin berdasarkan tenaga bebas penambatan 
serta jarak interaksi antara residu mangkin, Glu53 dan His296. Sementara itu, 
penambahan Ca2+ mengakibatkan kehilangan interaksi antara residu Glu53 dengan 
sphingomyelin. 
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PRODUCTION OF DERMAL BIOACTIVES IN SELECTED 
LACTOBACILLI AND BIFIDOBACTERIA, WITH SPECIAL FOCUS ON 
SPHINGOMYELINASE ACTIVITY OPTIMISATION IN LACTOBACILLUS 
RHAMNOSUS FTDC 8313 IN THE PRESENCE OF MN2+ AND MG2+ 
 
ABSTRACT 
Lactobacilli and bifidobacteria are the most common genera of probiotics 
with documented potentials on gut health. Recent studies suggested that such 
potentials can be extended beyond gut well-being, such as that of dermal health. This 
study was aimed to evaluate the production of bioactives that are essential for skin 
health from either lactobacilli or bifidobacteria grown in milk. Lipoteichoic acid 
content in the cell wall fraction was higher (P < 0.05) in Lactobacillus rhamnosus 
FTDC 8313 and Bifidobacterium longum BL 8643 compared to the other strains 
studied. Meanwhile, all strains studied showed equal concentration of cell wall 
peptidoglycan. Our results showed that lactobacilli produced higher concentration of 
hyaluronic acid and diacetyl than bifidobacteria. Strains of lactobacilli and 
bifidobacteria studied also produced acid and neutral sphingomyelinase (SMase), 
enzymes that generate ceramides which subsequently play important roles in 
development of physical barriers in the stratum corneum (SC).  
Sphingomyelinase activity in L. rhamnosus FTDC 8313 was also optimized 
using divalent metal ions via response surface methodology. Using a full-factorial 
design for factors screening, only magnesium sulphate (MgSO4) and manganese 
sulphate (MnSO4) significantly (P < 0.001) influenced SMase activity while the 
effects of calcium sulphate (CaSO4) was insignificant (P > 0.05). A central 
composite design matrix (alpha value of ± 1.414) was generated with two 
xvii 
 
independent factors namely, MnSO4 and MgSO4. Three dimensional response 
surface predicted an optimum point with maximum SMase activity of 6.52 mU ml-1, 
by a combination of 3.85 mmol L-1 of MnSO4 and 3.33 mmol L-1 of MgSO4. 
Validation data obtained showed a deviation of 1.07 % from the predicted value, 
ascertaining the predictions and the reliability of the regression model used. Effects 
of divalent metal ions on growth properties and production of hyaluronic acid, 
diacetyl, peptidoglycan, lipoteichoic acid, lactic and acetic acids in the region of 
optimized SMase activity were also evaluated using 3D response surfaces.  
The effects of the divalent metal ions on sphingomyelinase activity were 
further evaluated via molecular simulations. Molecular docking demonstrated that 
the addition of Mn2+ and Mg2+ into the active site of SMase improved the binding 
affinity between the SMase and sphingomyelin based on it free energy of binding as 
well as the interaction distances between the important catalytic residues Glu53 and 
His296. Meanwhile, addition of Ca2+ appeared to result in a loss of interaction 
between the Glu53 residues with sphingomyelin. 
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CHAPTER 1- INTRODUCTION  
1.1 Background 
Lactobacilli and bifidobacteria are the most commonly documented genera of 
probiotics used for human consumption. Derived from the Greek word meaning “for 
life”, probiotics have been defined as “live microorganisms which, when 
administered in adequate amount confer a health benefit to the host” (FAO/WHO, 
2001). Probiotics have been extensively reviewed for decades, emphasizing on 
improving general gut health such as alleviating intestinal disorders and maintaining 
a healthy gastrointestinal microflora. 
Recently, more studies showed that probiotics may exert other health 
promoting effects beyond gut well-being, attributed to the rise of the gut-brain-axis 
correlations. The gut-brain-skin axis concept, as proposed by Arck et al. (2010) 
suggests that modulation of the microbiome by deployment of probiotics can also 
exert profound beneficial effects such as on skin inflammation and skin homeostasis. 
Some of these new benefits include skin health such as improving atopic eczema, 
atopic dermatitis, healing of burns and scars, skin rejuvenating properties, and 
improving skin innate immunity (Arck et al., 2010). Increasing evidences have also 
showed that bacterial compounds such as cell wall fragments, their metabolites and 
dead bacteria can elicit certain immune responses on the skin and improve skin 
barrier functions.  
Increasing demand for natural formulations for skin care in the market 
indicate that there is an emerging new potential of probiotics in dermatology. It is 
estimated that the global probiotics market would grow at a compound annual 
growth rate of 13 % from 2009-2014 (Koncept Analytics, 2010). In general, non-
intestinal applications of lactobacilli and bifidobacteria are few and there is little 
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information available on the use of generally recognized as safe (GRAS) 
microorganisms for production of bioactive metabolites for skin applications. Natural 
cell components and metabolites may be the preferred choice in cases where safety 
and side-effects are of concern. Moreover, cell components and metabolites are more 
stable than viable cells at room temperature, and are thus more suitable for various 
product developments (Ouwehand et al., 2010).   
Medium optimization, via the addition of metal ions such as manganese 
(Mn2+) and magnesium (Mg2+) ion, has been documented to have an effect on 
increasing cellular growth and metabolite production (Fitzpatrick et al., 2001). These 
divalent metal ions are required as an essential cofactor for stimulating the activity of 
metalloenzymes such as aminopeptidases, dipeptidases, Mn-catalases, D-xylose 
isomerase, L-arabinose isomerase, ribozymes, etc. Sphingomyelinase (SMase) is one 
of the metalloenzymes responsible in generating a family of ceramides and 
phosphorylcholine from glucosylceramide and sphingomyelin precursors for the 
development of extracellular lipid bilayers in the SC (Jensen et al., 2005). Additions 
of the divalent metal ions into growth media have also been reported to result in 
increased growth of probiotics such as Lactobacillus bifermantans (Givry and 
Duchiron, 2008). For these reasons, by using response surface methodology, medium 
optimization via the addition of divalent metal ions can be carried out on the selected 
strains to observe its effect on production of dermal bioactives such as SMase. 
Briefly, response surface methodology can be outlined as a compendium of statistical 
methods to determine and solve multivariate equations by utilising quantitative data 
from experiments (Liong and Shah, 2005). 
The effects of the divalent metal ions on SMase activity were further 
investigated via molecular simulations. Molecular simulation can be described as the 
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process of docking a small molecule to a macromolecule with the objective of 
observing and studying interactions between these molecules. Molecular docking has 
developed by leaps and bounds in the last decades in terms of technology and 
computing power, and today, it is a common practice to utilize molecular simulation 
to complement conventional wet laboratory research. Emergence of molecular 
simulation has opened new possibilities and ways to learn molecular interaction 
between molecules. 
 
1.2 Problem statement 
While many studies and patents have been published on the use of probiotic 
extracts for topical application on the skin, the mechanisms or the exact compounds 
underlying the benefits of bacterial extract on the skin however, remain unclear. 
Increasing demand for probiotic dermal formulations further boost the urge to 
understand the exact mechanisms of action. The potential benefits of lactobacilli and 
bifidobacteria are, however, dependent on selection of strains. We hypothesized that 
certain strains of lactobacilli and bifidobacteria could exert dermal benefits via 
production of inhibitive and bioactive compounds. To my knowledge, little emphasis 
has been given on such properties of lactobacilli and bifidobacteria.  
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1.3 Aims and objectives of research 
The main objective of this study was to evaluate the potential of lactobacilli 
and bifidobacteria in producing bioactives that are essential for skin defense and 
dermal health. This study was also aimed to optimize the production of the dermal 
bioactives and to further investigate the effects of the divalent metal ions on 
sphingomyelinase via molecular simulations. The specific objectives of this study 
were: 
1) To screen and evaluate the production of dermal bioactives including 
lipoteichoic acid, peptidoglycan, hyaluronic acid, diacetyl, lactic acid, acetic 
acid and sphingomyelinase among 15 selected strains of lactobacilli and 
bifidobacteria. 
2) To optimize the production of sphingomyelinase by Lactobacillus rhamnosus 
FTDC 8313 via response surface methodology upon addition of manganese 
ion, magnesium ion and calcium ion. 
3) To evaluate the growth of Lactobacillus rhamnosus FTDC 8313 and 
production of lipoteichoic acid, peptidoglycan, hyaluronic acid, diacetyl, 
lactic acid, acetic acid upon sphingomyelinase optimization. 
4) To evaluate the binding affinity and interaction between sphingomyelinase 
and sphingomyelin upon addition of manganese ion, magnesium ion and 
calcium ion via molecular simulations. 
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CHAPTER 2 – LITERATURE REVIEW 
2.1 Definition and characteristics of probiotics 
Derived from the Greek word “pro-bios” meaning “for life”, the word 
‘probiotics’ was initially used as an antonym of the word ‘antibiotic’. Interest in 
probiotics was dated back to Metchnikoff in 1907, who suggested that several 
intestinal bacteria produce useful substances against premature aging. It was later in 
1974 that probiotics were defined as “organisms or substances which contribute to 
intestinal microbial balance” (Parker, 1974). Since then, increasing interest on 
probiotics had mainly focused on improving general gut health. The definition of 
probiotics has been redefined throughout the years and it was defined as “live 
microorganisms that confer a health effect on the host when consumed in adequate 
amounts” (Guarner and Schaafsma, 1998). However, recent studies suggested that 
probiotics have great potentials beyond gut well-being and not only through oral 
consumption. Thus, one of the most accepted definition of probiotics is “live 
microorganisms which when administered in adequate amount confer a health 
benefit to the host” (FAO/WHO, 2001).  
A notable number of microbial species and genera have been known to 
exhibit functional characteristics typically associated with probiotic properties (Table 
2.1). For a microorganism to be defined as probiotic, it must possess the following 
requirements: 1) alive when administered, 2) have undergone controlled evaluation 
to document health benefits in the target host, 3) taxonomically defined microbe or 
combination of microbes (genus, species and strain level), and 4) safe for its intended 
use (Sanders, 2000).  
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Table 2.1  Microorganisms associated with probiotic properties 
Lactobacillus Bifidobacterium Enterococcus Streptococcus Lactococcus 
L. acidophilus 
L. brevis 
L. casei 
L. curvatus 
L. fermentum 
L. gasseri 
L. johnsonii 
L. reuteri 
L. rhamnosus 
L. salivarius 
 
B. adolescentis 
B. animalis 
B. breve 
B. infantis 
B. longum 
B. thermophilum 
E. faecalis 
E. faecium 
S. 
thermophilus 
L. lactis subsp. 
cremoris 
L. lactis subsp. 
lactis 
 
Propionibacterium Yeast  Others  
P. freudenreichii 
P. freudenreichii subsp. shermanii 
P. jensenii 
Kluyveromyces lactis 
Saccharomyces boulardii 
Saccharomyces cerevisiae 
Leuconostoc 
mesenteroides  
Pediococcus 
acidilactici  
(adapted from Caramia and Silvi, 2011) 
 
2.1.1 Lactobacillus 
Lactobacilli are among the most commonly studied genera of probiotics. The 
genus Lactobacillus represents the largest group within the family Lactobacillaceae, 
with 185 species and 28 subspecies listed to date (Euzéby, 2013). Originally isolated 
from the faeces of breast-fed infants in 1990, lactobacilli are characterized as gram-
positive, facultative anaerobes, non-sporulating and non-flagelated rods or 
coccobacilli (Gomes and Malcata, 1999). They have been identified as part of the 
normal oral, intestinal and vaginal microflora (Dal Bello et al., 2006; Mijač et al., 
2006). The most common Lactobacillus species isolated from human intestine 
includes L. acidophilus, L. salivarius, L. casei, L. plantarum, L. reuteri and L. brevis 
(Saito, 2004). Some species of lactobacilli has also been shown to be normal 
inhabitants of plant and vegetable material. Successful incorporation of lactobacilli 
into food system such as dairy, meat product, juice and fermented beverages, and in 
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grains and cereal products has proved the ability of lactobacilli to grow and persist in 
many diverse environments and conditions (Giraffa et al., 2010).  
Generally, there are two groups of species depending on the ability to ferment 
sugars; the homofermentative species which converts sugars mostly into lactic acid, 
and heterofermentative species which converts sugars into lactic acid, acetic acid, 
ethanol and carbon dioxide. However, some species of lactobacilli have the genetic 
and physiological wherewithal to ferment sugars by either pathway, and they are 
therefore referred to as facultative heterofermentative or obligate heterofermentative 
(Hutkins, 2006). The optimum temperature for growth of lactobacilli varies widely 
from 30˚C to 45˚C and pH 5.5 to 7.0 (Hutkins, 2006). 
 
2.1.2 Bifidobacterium 
Bifidobacterium strains, first isolated from faeces of breast-fed infant by 
Tissier in 1899, are major constituents of the microbiota that colonize the intestinal 
tract of animals and humans (Turroni et al., 2011). Due to the increasing evidence on 
their role in maintaining the gut health and well-being, bifidobacteria have become 
one of the most important probiotics used for human consumption. The genus 
Bifidobacterium is a member of the Bifidobacteriaceae family with 47 species and 9 
subspecies listed so far (Euzéby, 2013). They are gram-positive, non-sporeforming, 
non-filamentous and non-motile (Delcenserie et al., 2007). Bifidobacteria were 
classified in the genus Lactobacillus until the 1970s, when they were discovered to 
be phylogenitically distinct from the lactic acid bacteria, and are in an entirely 
different phylum i.e. Actinobacteria. The main species present in human are 
Bifidobacterium adolescentis, B. bifidum, B. infantis, B. longum and B. breve (Roy, 
2001). They are strictly anaerobic and catalase negative, with a temperature optima 
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between 37˚C and 41˚C and a pH optima for growth initiation between 6.5 and 7.0 
(Hutkins, 2006). They may differ in shapes and occur as short, curved rods, club-
shaped rods, or bifurcated Y-shaped rods (Gomes and Malcata, 1999). Bifidobacteria 
have also been reported to be isolated from a number of other environments such as 
anaerobic digester, sewage, honey bee intestine and fermented milk (Felis and 
Dellaglio, 2007). Their ability to utilize a wide array of carbohydrates, including 
non-digestible oligosaccharides that reach the colon, provides selective advantages in 
the colonic environment (Gibson et al., 1996). Bifidobacteria degrade hexoses 
through a peculiar metabolic pathway, the bifid shunt, or also known as fructose-6-
phosphate pathway (Wolin et al, 1998). 
 
2.2 Conventional health benefits of probiotics 
The benefits of probiotics in regulating gut health have been explored and 
recognized for over a century. During the last decades, more evidence on new roles 
of probiotics for gut health has been proposed (Table 2.2). There are various 
evidence to support the verification of such effects, from in vitro animal and human 
studies. One of the established and potential health benefits of probiotic organisms 
regarding gut health includes alleviation of lactose intolerance. Another main 
application of probiotic organisms has been the treatment and prevention of diarrhea. 
Evidence on the efficacy of probiotics in preventing diarrhea of various causes such 
as acute rotavirus diarrhea (Teran et al., 2008), antibiotic-associated diarrhea 
(Szajewska et al., 2006), Clostridium difficile associated diarrhea (McFarland, 2006), 
radiation-induced diarrhea (Giralt et al., 2008) and traveler’s diarrhea (McFarland, 
2007) have been well explored.  
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By improving the intestinal microbial balance, probiotics have been reported 
to exert beneficial effects such as inhibiting growth of pathogenic microorganisms 
and preventing gut inflammation. The antimicrobial mechanisms of probiotics 
include competition for nutritional sources and adhesion sites in the intestines, 
secretion of antimicrobial substances and toxin inactivation (Collado et al., 2009). 
Probiotics have also been reported to exert important gut health promoting activities 
by increasing metabolic activity of the intestinal cells, stimulate immune response 
without harmful effects and enhancing intestinal integrity (Nissen et al., 2009).  
 
Table 2.2  Role and benefits of probiotic bacteria in the gastrointestinal tract 
Benefits of probiotic bacteria Reference 
Improved lactose tolerance (Vesa et al., 1996) 
Control inflammatory bowel disease (Campieri and Gionchetti, 
1999) 
Improved mucosal immune function, mucin secretion 
and prevention of disease 
(MacFarlane and 
Cummings, 2002) 
Competitive exclusion of pathogens (Lee et al., 2003) 
Protection against infection (Corr et al., 2007) 
Preventing injury of the epithelial cell barrier  (Johnson-Henry et al., 2008) 
Return to pre-antibiotic baseline flora (Engelbrektson et al., 2009) 
Reduction in irritable bowel disease symptoms (MacFarlane et al., 2009) 
Lowered incidence of diarrhea (Collado et al., 2009) 
Alleviate food allergy symptoms  (del Giudice et al., 2010) 
Reduction in risk factors for colon cancer (Liong et al., 2011) 
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2.3 New roles of probiotics 
Recently, clinical studies have reported that probiotics may exert other health 
promoting effects beyond gut well-being. Probiotics work through several 
interrelated mechanisms to promote health at the molecular level. They favourably 
alter the composition and activities of the intestinal microbial community, thus 
potentially reversing major contributors to chronic disease.  
Probiotics have been documented to lower blood cholesterol levels (Ooi and 
Liong, 2010). Past in vivo study showed that the administrations of probiotics 
successfully reduced serum/plasma total cholesterol levels in mildly to moderately 
hypercholesterolaemic subjects after 12 weeks (Ataie-Jafari et al., 2009). Also, Park 
et al. (2007) reported that hypercholesterolaemic rats showed a reduction of very low 
density lipoprotein, intermediate density lipoprotein and low density lipoprotein 
cholesterol after being fed with L. acidophilus ATCC 43121 for 21 days. It has been 
proposed that there were five possible mechanisms for the removal of cholesterol, 
namely assimilation of cholesterol during growth, binding of cholesterol to cellular 
surface, deconjugation of bile salt, disruption of cholesterol micelle and bile salt 
hydrolase activity (Lye et al., 2010). 
 Probiotics have also been documented to exert antihypertensive effects via 
the modulation of lipid profiles, insulin, rennin and sexual hormones (Yeo and Liong, 
2010). Experimental evidence involving in vivo trials has exhibited positive results. 
In a double-blind, placebo-controlled, randomized study involving 94 hypertensive 
subjects, Jauhiainen et al. (2005) found that the consumption of 150 mL of L. 
helveticus fermented milk twice a day for 10 weeks successfully decreased systolic 
blood pressure and diastolic blood pressure by 4.1 mm Hg and 1.8 mm Hg, 
respectively. One of the proposed mechanisms leading to the antihepertensive effects 
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is that probiotics could convert milk protein into bioactive peptides such as 
angiotensin I-converting enzyme that plays an important physiological role in 
regulating blood pressure and fluid and salt balance in mammals (Yamamoto and 
Takano, 1999). 
Another potential role of probiotics includes treatment of urogenital 
infections (Abad and Safdar, 2009). Several mechanisms of action have been 
proposed for the potential beneficial effect. Urogenital infections in women are often 
caused by an alteration in the local flora with a transformation from predominance of 
lactobacilli to coliform pathogens (Sweet, 2000). Thus, the ability of probiotics to 
exhibit antimicrobial activity remains as one of the promising alternatives for the 
prevention or treatment of urogenital infections. Also, probiotics offer protection by 
producing biosurfactants, which interfere with growth and adhesion of pathogenic 
microorganisms such as Escherichia coli and Enterococcus faecalis to uro-epithelial 
cells (Velraeds et al., 1996). 
Potential of probiotics in the treatment and reduction of allergic reactions 
have also been proposed (Michail, 2009). Allergic disorders are often associated with 
a shift of Th1/Th2 cytokine balance towards a Th2 response. Probiotics have been 
reported to potentially modulate the toll-like receptors and the proteoglycan 
recognition proteins of enterocytes, leading to activation of dendritic cells and 
suppression of Th2 responses (Winkler et al., 2007). Several in vivo as well as in 
vitro and animal studies have suggested the potential use of probiotics in allergic 
diseases such as atopic dermatitis (Kalliomaki et al., 2007) and allergic rhinitis 
(Giovannini et al., 2007). 
Probiotics have also been suggested as alternatives for prevention of dental 
caries (Soderling, 2012). It has been reported that short-term consumption of L. 
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rhamnosus GG, L. reuteri and B. lactis BB-12 resulted in a reduction of 
Streptococcus mutans, a caries-promoting bacteria (Nase et al., 2001, Stamatova and 
Meurman, 2009). Also, the amount of dental plaque was reduced. In addition, results 
from human studies conducted by Nase et al. (2001) showed that L. rhamnosus GG 
fermented milk reduced caries occurrence in 3-4 years old children. 
  Studies on the effects of probiotic consumption in reducing the risks of 
cancers appear promising as many in vitro and in vivo studies have reported that 
probiotics reduce the risk, incidence and number of tumors in the colon, liver and 
bladder (Kumar et al., 2010). According to Saikali et al. (2004), probiotics may 
beneficially modulate several major intestinal functions: detoxification, colonic 
fermentation, transit, and immune status, which may accompany the development of 
colon cancer. Meanwhile, animal studies consistently show a reduction in chemically 
induced colorectal tumor incidence and aberrant crypt formation upon probiotic 
administration (Saikali et al., 2004). 
Other documented potentials of probiotics include alleviation of 
postmenopausal symptoms (de Vrese, 2009), facilitation of mineral absorption 
(Scholz-Ahrens et al., 2007), amelioration of arthritis (Baharav et al., 2004) and 
exhibition of antioxidative effects (Songisepp et al., 2004). 
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2.4 Human Skin 
2.4.1 Structure and function 
The natural function of the skin is to protect the body by forming an effective 
barrier between the organism and the environment; preventing invasion of pathogens 
and fending off chemical and physical assaults, as well as the unregulated loss of 
water and solutes (Proksch et al., 2008). The skin is composed of two main layers; 
the epidermis and the dermis. The subcutaneous layer, located beneath the dermis, 
comprises mainly of loose areolar and fatty connective tissue (Figure 2.1). The 
epidermis is a thin protective outer layer and can be further divided into several 
stages of differentiation of cells. The dermis provides mechanical strength and is 
made up of dense fibroelastic connective tissue (collagen and elastic fibers) within a 
hydrated glycoprotein matrix (Sanders et al., 1999).  
 
Figure 2.1: The skin and its appendages. (adapted from: McGrath et al., 2008) 
 
The main barrier of the skin is located at the superficial layer of the epidermis, 
the SC. It can be depicted as flat, protein-rich hexagonal corneocytes embedded in a 
lipid-rich intercellular space. In the normal human skin, the corneocytes of SC are 
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extremely flat structures with widths of about 30µm and thickness of 0.3µm 
(Forslind et al., 2003). The major lipid classes in the SC are ceramides, free fatty 
acids and cholesterol and changes in the lipid composition will lead to a disturbed 
skin barrier (Proksch et al., 2008). It has been reported that the SC is not a dead 
tissue, but possesses multiple types of catalytic activities in both the cytosolic and 
membrane/extracellular compartments (Elias, 2007).  
Although the physical barrier consists mainly of SC, the nucleated epidermal 
layers also contributes to the barrier through tight, gap and adherens junctions, as 
well as through desmosomes and cytoskeletal elements (Proksch et al., 2008). While 
removal of SC by tape-stripping resulted in a low to moderate increase of 
transepidermal water loss, the loss of entire epidermis leads to a severe disturbance 
in barrier function. Besides preventing excessive water loss, the nucleated epidermal 
layers also prevents the entry of harmful substances into the skin (Honari, 2004). 
 
2.4.2 Skin microbiota 
Skin, as the largest human organ, is constantly exposed to microorganisms in 
the environment. As a result, it harbors a plethora of different groups of 
microorganisms that make up the human skin microbiota. For the past decades, many 
studies have focused in defining the microbial inhabitants of human skin, especially 
on descriptive features such as their association with infection, their interactions with 
other microbes and their stability over time (Rosenthal et al., 2011). To date, the 
number of bacteria identified from human skin has expanded significantly, and will 
probably continue to increase as genotyping techniques advance. 
Bacterial skin populations can be categorized as transient (contaminant, non-
reproducing), temporary resident (not typically resident, yet can colonize) and 
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resident (growing, reproducing). According to a recent review by Kong and Segre 
(2012), the ‘normal’ resident skin flora includes Staphylococcus, Corynebacterium, 
Propionibacterium and Pseudomonas as determined by traditional cultivation 
methods. Using the 16S rRNA gene-based methods, the presence of 
Corynebacterium spp., Propionibacterium spp. and Staphylococcus spp. was 
confirmed to exist on human skin. However, it has to be kept in mind that whether 
the microorganism is pathogenic or not depends on the profile of the human immune 
system rather than ‘‘the inherent properties of the microbe’’ itself (Cogen et al., 
2008). 
Staphylococcus epidermidis, the most common clinical isolate of the 
cutaneous microbiota, is a Gram-positive coccus found in clusters. As a major 
inhabitant of the skin and mucosa it is thought that S. epidermidis comprises greater 
than 90% of the aerobic resident flora (Cogen et al., 2008). S.epidermidis is harmless 
under normal condition, if not as a mutual on the skin’s surface. But for immune-
compromised host, it is recognized as an important pathogen involved in nosocomial 
bloodstream infections, cardiovascular infections, and infections of the eye, ear, nose 
and throat (Vuong and Otto, 2002). 
Staphylococcus aureus is known widely as one of the leading human 
pathogen, particularly those strains that produce superantigenic toxins. S. aureus 
causes clinical disease ranges from minor and self-limited skin infections to invasive 
and life-threatening diseases. Examples of S. aureus skin infections include 
folliculitis, furuncles, impetigo and subcutaneous abscesses (Iwatsuki et al., 2006). 
However, studies have suggested that colonization by S. aureus is certainly not 
synonymous with infection. In fact, S. aureus found on healthy human skin and in 
nasal passages are acting as a commensal rather than a pathogen (Cogen et al., 2008). 
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Coryneforms are gram-positive pleomorphic bacilli included as skin 
commensals and are classified as either lipophilic or nonlipophilic. This group 
includes Corynebacterium sp., Propionibacterium sp., Dermabacter sp., and 
Brevibacterium sp. Propionibacterium acnes is by far the most dominant anaerobic 
coryneform on the skin and is abundant on the skin of the scalp, forehead and back. 
Dermabacter and Brevibacterium sp. prefer glabrous, human skin such as the toe 
webs and may cause ‘foot odor’ (Chiller et al., 2001). 
Pseudomonas aeruginosa is another common bacterial species which is 
considered as normal constituent of a human’s natural microflora and lives 
innocuously on human skin and in the mouth. However, they are able to infect 
practically any tissue with which they come into contact. P.aeruginosa occasionally 
causes dermatitis or deeper soft-tissue infections. Dermatitis occurs when skin comes 
into contact with infected water such as in hot tubs (Cogen et al., 2008). 
There are many elements that potentially contribute to the composition of 
microbial communities in skin. External factors include ambient humidity, seasonal 
weather conditions, previous antibiotic treatment, clothing type, use of lotions, 
creams, cleansers, deodorants or anti-perspirants, hygiene frequency and other 
environmental surfaces interaction. Intrinsic factors such as age, genetic makeup and 
host immune system also influence the composition of skin microbiota. 
 
2.4.3 Skin defense mechanisms 
Although our skin is permanently threatened by various potential pathogenic 
microorganisms, it is surprisingly highly resistant against infections. The skin’s 
innate immunity, often defined as a rapid, first line defense system is responsible in 
providing protection against infection and degradation.  The defense system 
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comprises both physical and chemical constitutive protection and the response 
process is elicited once the basic barrier is breached (Gallo and Nizet, 2008). 
Skin as a protective organ covers the body and accomplishes multiple 
defensive functions. The structural integrity of the body surfaces, i.e., the skin, forms 
an effective barrier to initial lodgment or penetration by microorganisms. The intact 
skin also represents a barrier to the uncontrolled loss of water, proteins, and plasma 
components (Darlenski et al., 2008). Most of the defensive (barrier) functions of the 
epidermis localize to the SC, which limits pathogen colonization through its low 
water content, acidic pH, resident (normal) microflora, and surface-deposited 
antimicrobial lipids (Elias, 2007). The SC is the outermost layer of the epidermis that 
results from the terminal differentiation of the keratinocytes. It forms the primary 
layer of protection from the external environment and is composed of highly cross-
linked proteinaceous cellular envelopes with extracellular lipid lamellae consisting of 
ceramides, free fatty acids, and cholesterol (Proksch et al., 2008).  
Over the last decades the simple two-compartment model (‘‘brick-and-
mortar”) of the SC structure evolved to a concept presenting SC as a system with a 
regulated metabolic activity and as a biosensor for external factors such as regulating 
proteolytic activity, DNA synthesis, and lipid synthesis (Darlenski et al., 2008). 
Besides its physical barrier against invading microorganisms, the skin has the ability 
to produce a number of antimicrobial peptides and proteins that participate in the 
innate host defense (Niyonsaba and Ogawa, 2005). These antimicrobial agents are 
strongly active against a wide spectrum of various pathogens such as bacteria, 
viruses and fungi. The resulting local accumulation of antimicrobial proteins offers a 
fast and very efficient way to prevent microbes from establishing an infection 
(Harder and Schroder, 2005). In addition to their antimicrobial properties, they also 
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contribute to cutaneous wound healing and perform a series of immunomodulatory 
functions, thus acting not only as proinflammatory agents but also as a key link 
between the innate and the adaptive immune system (Niyonsaba et al., 2007). Some 
skin antibacterial agents from the epithelium such as defensins and cathelicidins have 
the ability to chemoattract neutrophils or other inflammatory cells after their 
migration to sites of infection or injury (Niyonsaba and Ogawa, 2005). 
Defensins are one of the most common types of antimicrobial peptides 
participating in the host response against bacterial infections and are expressed in 
multiple tissues in the body (Menendez and Finlay, 2007). They are small cationic 
peptides of 3—5 kDa (mature form peptides) and are characterized by six cysteine 
residues forming three intramolecular disulfide bridges. Defensins are divided into α- 
and β-defensins based on the distribution of the cysteines and linkages of the 
disulfide bonds (Niyonsaba and Ogawa, 2005). To date, six human α-defensins have 
been identified, mainly packaged in azurophil granules of neutrophils or secreted by 
intestinal Paneth cells (Oppenheim et al., 2003). Human β-defensins on the other 
hand, are constitutively expressed in various mucosa and epithelial cells where they 
can be up-regulated in response to infectious and inflammatory stimuli. So far, six 
human β-defensins (hBDs), hBD-1 through hBD-6, have been identified but only 
hBD-1, hBD-2 and hBD-3 are expressed in the skin (Guaní -Guerra et al., 2010; 
Sørensen et al., 2005). 
hBD-1 is a 3.9 kDa peptide of 36 amino acid residues and is the first isolated 
human β-defensin. It is expressed constitutively in epidermal keratinocytes and 
shows antimicrobial activity against predominantly Gram-negative bacteria like E. 
coli and P. aeruginosa (Pivarcsi et al., 2005). The expression of hBD-1 is also 
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inducible in keratinocytes of human skin by microbe-derived molecules such as 
lipopolysaccharide (LPS) and peptidoglycan (Sørensen et al., 2005).  
The second human β-defensin, hBD-2, consists of 41 amino acids. It is a 4.3-kDa 
peptide, primarily isolated from extracts of lesional scales of psoriatic skin and is 
expressed in the skin as well as in urinary, gastrointestinal, and respiratory epithelia 
(Guaní -Guerra et al., 2010). hBD-2 is inducible upon stimulation of epithelial cells 
by contact with microorganisms such as P. aeruginosa or cytokines such as TNF-
alpha and IL-1 beta (Schröder and Harder, 1999). Purified staphylococcal cell-wall 
components, LTA and peptidoglycan has been suggested to stimulate the production 
of hBD-2 via Toll-like receptor 2 (TLR2) (Dziarski and Gupta, 2005). It has also 
been suggested that a diminished expression of antimicrobial peptides such as hBD-2 
might be one reason to explain why patients with atopic dermatitis often suffer from 
recurrent skin infections caused particularly by S. aureus (Niyonsaba and Ogawa, 
2005). 
hBD-3 is a 5.1-kDa antimicrobial peptide with 45 amino acid residues (Harder 
and Schroder, 2005). The same authors have also mentioned that hBD-3 
demonstrated a salt-insensitive broad spectrum of potent antimicrobial activities 
against many potentially pathogenic microbes including the multiresistant S. aureus. 
This molecule is expressed either constitutively or induced upon a challenge, and a 
growing evidence indicates the involvement of such molecules in adaptive immunity 
as well (Dhople et al., 2006). Also, hBD-3 induces cytokine production from human 
keratinocytes and stimulates monocyte migration (Niyonsaba and Ogawa, 2005). 
Another major family of antimicrobial peptides with potential importance in 
human skin defense belongs to cathelicidins. Cathelicidins share a conserved cathelin 
pro-domain and a variable antimicrobial peptide domain that is released from the 
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parent molecule by proteolytic processing (Zanetti et al., 2000). However, only 
cathelicidin hCAP18 or its mature antimicrobial peptide LL-37 is typically 
upregulated in human keratinocytes. LL-37 exhibited a broad-spectrum antimicrobial 
activity against a variety of Gram-positive and Gram-negative bacterial, fungal and 
viral pathogens (Niyonsaba and Ogawa, 2005). It has been suggested that 
keratinocyte synthesis of cathelicidin play an important role in skin immunity. It 
forms an active part of the antimicrobial defense barrier that is independent of 
circulating immune cells (Braff et al., 2005). Using a mouse model, it has also been 
suggested that cathelicidin LL-37 not only contributes to clearance of bacteria, but 
also offers systemic protection against the detrimental effects of massive microbial 
invasion (Nizet et al., 2001). In addition, LL-37 also plays a part in epithelial cell 
proliferation and re-epithelialization of human skin wounds (Heilborn et al., 2003). 
Lysozyme is a peptidoglycan N-acetyl-muramoylhydrolase, also known by 
the trivial name muramidase. Lysozyme is expressed in human skin and the level 
was found three-fold higher in the epidermal portion than the dermal one (Niyonsaba 
and Ogawa, 2005). The substrate of lysozyme is peptidoglycan, which is a major 
component of bacterial cell wall. Hydrolysis of peptidoglycan results in cell lysis 
(Niyonsaba and Ogawa, 2005). Although lysozyme is mainly a Gram-positive 
bacteria-killing antimicrobial peptide, it is also active against Gram-negative bacteria 
such as E. coli and P. aeruginosa (Schroder and Harder, 2006). Apart from its 
antimicrobial properties, lysozyme has been demonstrated to play a role in the 
control of inflammation when lysozyme M-deficient mice developed much more 
severe lesions than wild-type mice (Ganz et al., 2003). 
 Keratinocytes also produce RNase 7, a 14.5-kDa antimicrobial ribonuclease 
that exhibits antimicrobial activity against various pathogenic microorganisms, 
21 
 
including S. aureus, P. aeruginosa, Propionibacterium acnes, Candida albicans and 
E. coli (Harder and Schroder, 2005). RNase 7 is constitutively expressed in normal 
healthy skin and is further inducible upon microbial stimulation, suggesting that it 
may play an important role in the innate immune defense system of human epithelia 
(Harder and Schroder, 2002). 
In addition to the antimicrobial peptides mentioned above, human skin has 
also been shown to produce other antimicrobial peptides such as elafin, psoriasin, 
dermicidin, antileukoprotease, adrenomedullin, and nuetrophil gelatinase-associated 
lipocalin for protection of the skin against microbial infection (Niyonsaba and 
Ogawa, 2005). 
 
2.5 Probiotic applications for dermal health 
Probiotics have also been documented to exert dermal potentials such as 
improving atopic eczema, atopic dermatitis, healing of burns and scars, having skin 
rejuvenating properties, and also improving the skin’s innate immunity. The gut-
brain-skin axis concept, as proposed by Arck et al. (2010) suggested that modulation 
of the microbiome by deployment of probiotics can exert profound beneficial effects 
such as on skin inflammation and skin homeostasis. Accordingly, a significant 
improvement on the course of atopic dermatitis has been reported in 230 infants 
subjected to probiotic-supplemented elimination diets in a randomized double-blind 
manner for four weeks (Viljanen et al., 2005). Meanwhile, a study involving 56 
patients with acne showed that the consumption of a Lactobacillus-fermented dairy 
beverage for 12 weeks improved clinical aspects of acne (Kim et al., 2010). It has 
been suggested that healthy skin may also benefit from the oral ingestion of probiotic 
bacteria (Krutmann, 2009). In a double-blind, randomized clinical study involving 72 
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healthy women with dry and sensitive skin, it was reported that the SC barrier 
function significantly improved upon consumption of fermented dairy product as 
compared to placebo product (Krutmann, 2009). Also, supplementation of hairless 
mice with L. johnsonii has been reported to provide protection of the skin immune 
system against ultraviolet B radiation-induced immunosuppressive effects. Similarly, 
using a human study, it has been suggested that oral consumption of probiotics may 
represent a novel approach to protect the skin immune system against ultraviolet 
radiation. 
While approaches based on the oral application of probiotic strains appear 
promising, human clinical studies suggested that probiotic exert dermal benefits not 
only through the gastrointestinal route but also upon topical applications. Using an in 
vitro study, Iordache et al. (2008) has demonstrated that cell free supernatant of 
lactic acid bacteria with probiotic potentials including L. plantarum, L. casei and 
Enterococcus faecium inhibited the expression of soluble virulence factors by 
opportunistic dermal pathogens such as Staphylococcus aureus and Pseudomonas 
aeruginosa and decreased their adherence capacity to the cellular substrate 
represented by HeLa cells. Using an ex vivo human skin explants model, (Gueniche 
et al., 2010) found a statistically significant improvement (P < 0.05) following 
application of cell lysate from B. longum sp. versus placebo in various parameters 
associated with inflammation including decrease in vasodilation, oedema, mast cell 
degranulation and tumor necrosis factor-alpha (TNF-α) release. The potentials of 
probiotics in dermal application have also been evaluated in several in-vivo studies 
(Table 2.3). 
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Table 2.3. In-vivo potential of probiotics in dermal applications   
Treatment Strains involved Experimental design Dose and duration Effects ref 
Atopic 
eczema/ 
dermatitis 
L. rhamnosus GG 
ATCC53103 
Randomized, double-blind, 
placebo-controlled clinical 
trial to 230 infants with 
atopic eczema/dermatitis 
syndrome 
 
Administration of 5 x 
109 CFU; twice daily for 
4 weeks 
· Greater reduction in Severity 
Scoring of Atopic Dermatitis 
(SCORAD) of IgE-sensitized 
infants as compared to the placebo 
group  
Viljanen et al. 
(2005) 
Resistant 
childhood 
atopic eczema  
L. rhamnosus TB Open label non-randomized 
clinical observation of 14 
cases of pediatric patients 
(ages of 8 months to 64 
months) 
 
Administration of cell 
lysate (300 mg to 500 
mg daily) for 1 month 
· Marked improvements in eczema 
symptoms scores, daytime 
irritation and nighttime 
disturbances scores 
Hoang et al. 
(2010) 
Sensitive skin B. longum sp Randomized, double-blind, 
placebo-controlled clinical 
trial to 66 female volunteers 
with reactive skin 
Topical application of 
cream containing 10% 
Cell lysate; twice a day 
for 2 months 
 
· Decrease skin sensitivity score 
· Strengthen skin’s natural barrier 
Guéniche et al. 
(2010) 
Wound 
healing 
Probiotic mixture 
in kefir 
Randomized, double-blind, 
placebo-controlled clinical 
trial to 56 male Wistar rats 
with burn wounds infected 
with Pseudomonas 
aeruginosa (ATCC 27853) 
Topical application of 
gel containing 50% kefir 
extract; twice a day for 1 
week 
· No microbial contaminations were 
observed in the burn wounds; 
· Wound size significantly lower (P 
< 0.01) as compared to base gel 
and untreated groups as well as 
silver sulfadiazine treated group.  
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2.6 Dermal bioactives from probiotics 
There is increasing evidence that bacterial compounds such as cell wall 
fragments, their metabolites and dead bacteria can elicit certain immune responses on 
the skin and improve skin’s barrier function. Cell free supernatant of lactic acid 
bacteria with probiotic potentials have been demonstrated to exert antimicrobial and 
immunomodulatory activity, suggesting the use of probiotic in non-viable forms 
(Iordache et al., 2008). Natural cell components and metabolites may be the 
preferred choice in cases where the delivery of live cells is not possible. Moreover, 
cell components and metabolites are more stable than viable cells at room 
temperature, and are thus more suitable for topical applications.  
 
2.6.1 Lipoteichoic acid 
Lipoteichoic acid (LTA) is a group of membrane-anchored molecules formed 
by linking a hydrophilic polyphosphate polymer to a glycolipid (Fischer, 1988). It is 
a structural component of the cell walls of Gram-positive bacteria and plays a vital 
role in the growth and physiology of the bacteria. Lipoteichoic acid has been 
reported as one of the immune-stimulating component not only to pathogenic but 
also non-pathogenic Gram-positive bacteria. Previous studies showed that LTA can 
function as an important pathogen-associated molecular pattern, leading to 
production of proinflammatory cytokines, nitric oxide, activation of nuclear 
transcription factor (NF-ĸB) and other proinflammatory mediators (Lebeer et al., 
2012). Inflammatory response is an attempt by the host’s body to restore and 
maintain homeostasis following an infection or injury. LTA from pathogenic Gram 
positive bacteria such as S. aureus can however cause excessive inflammation, 
leading to the development of systemic inflammatory response syndrome such as 
